Therapie chronisch entzündlicher Darmerkrankungen mit Azathioprin, 6-Mercaptopurin und 6-Thioguanin

Azathioprin, 6-Mercaptopurin (6-MP) bzw. 6-Thioguanin nehmen sowohl in der immunsuppressiven wie auch in der zytostatischen Therapie einen besonderen Stellenwert ein. Die Gesamtverordnungszahlen für Azathioprin für das Jahr 2000 lagen nach Angaben des Arzneiverordnungsreports bei 320 900 [42]. In der gastroenterologischen Arzneimitteltherapie in Deutschland wird Azathioprin bevorzugt, währenddessen z. B. in den USA auch 6-MP vergleichsweise häufig verordnet wird. Das Indikationsspektrum für Azathioprin in der Gastroenterologie umfasst neben der Autoimmunhepatitis und der primär sklerosierenden Cholangitis v. a. die Therapie chronisch entzündlicher Darmerkrankungen (CED). Die vorliegende Arbeit gibt einen Überblick zur klinischen Pharmakologie von Azathioprin bei der Behandlung des Morbus Crohn (MC) und der Colitis ulcerosa (CU), wobei Aspekte zur Arzneimittelsicherheit bzw. zur Wirksamkeit von Azathioprin besonders berücksichtigt werden.

1 Unterstützt durch die Robert Bosch-Stiftung, Stuttgart und das BMBF (FKZ 01 GG 9846)

Literatur

• 1 Aithal G P, Mansfield J C. Review article: the risk of lymphoma associated with inflammatory bowel disease and immunosuppressive treatment.  Aliment Pharmacol Ther. 2001;  15 1101-1108
• 2 Andersen J B, Szumlanski C, Weinshilboum R M, Schmiegelow K. Pharmacokinetics, dose adjustments, and 6-mercaptopurine/methotrexate drug interactions in two patients with thiopurine methyltransferase deficiency.  Acta Paediatr. 1998;  87 108-111
• 3 Ansari A, Hassan C, Duley J. et al . Thiopurine methyltransferase activity and the use of azathioprine in inflammatory bowel disease.  Aliment Pharmacol Ther. 2002;  16 1743-1750
• 4 Bär U, Becker H, May B. et al . Azathioprine pharmacokinetics in animal experiment and in patients with chronic liver diseases.  Verh Dtsch Ges Inn Med. 1973;  79 943-946
• 5 Baert F, Rutgeerts P. 6-Thioguanine: a naked bullet? (Or how pharmacogenomics can make old drugs brand new).  Inflamm Bowel Dis. 2001;  7 190-191
• 6 Bebb J R, Aithal G P, Logan R P. Immunosuppression, IBD, and risk of lymphoma.  Gut. 2002;  51 296
• 7 Belaiche J, Desager J P, Horsmans Y, Louis E. Therapeutic drug monitoring of azathioprine and 6-mercaptopurine metabolites in Crohn disease.  Scand J Gastroenterol. 2001;  36 71-76
• 8 Bouhnik Y, Lemann M, Mary J Y. et al . Long-term follow-up of patients with Crohn’s disease treated with azathioprine or 6-mercaptopurine.  Lancet. 1996;  347 215-219
• 9 Campbell S, Kingstone K, Ghosh S. Relevance of thiopurine methyltransferase activity in inflammatory bowel disease patients maintained on low-dose azathioprine.  Aliment Pharmacol Ther. 2002;  16 389-398
• 10 Colombel J F, Ferrari N, Debuysere H. et al . Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn’s disease and severe myelosuppression during azathioprine therapy.  Gastroenterology. 2000;  118 1025-1030
• 11 Connell W R, Kamm M A, Dickson M, Balkwill A M, Ritchie J K, Lennard-Jones J E. Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease.  Lancet. 1994;  343 1249-1252
• 12 Connell W R, Kamm M A, Ritchie J K, Lennard-Jones J E. Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience.  Gut. 1993;  34 1081-1085
• 13 Cuffari C, Theoret Y, Latour S, Seidman G. 6-Mercaptopurine metabolism in Crohn’s disease: correlation with efficacy and toxicity.  Gut. 1996;  39 401-406
• 14 Cuffari C, Hunt S, Bayless T. Utilisation of erythrocyte 6-thioguanine metabolite levels to optimise azathioprine therapy in patients with inflammatory bowel disease.  Gut. 2001;  48 642-646
• 15 Dewit O, Vanheuverzwyn R, Desager J P, Horsmans Y. Interaction between azathioprine and aminosalicylates: an in vivo study in patients with Crohn’s disease.  Aliment Pharmacol Ther. 2002;  16 79-85
• 16 Dubinsky M C, Lamothe S, Yang H Y. et al . Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease.  Gastroenterology. 2000;  118 705-713
• 17 Ekbom A, Helmick C, Zack M, Adami H O. Extracolonic malignancies in inflammatory bowel disease.  Cancer. 1991;  67 2015-2019
• 18 Elion G B. The purine path to chemotherapy.  Science. 1989;  244 41-47
• 19 Evans W E, Hon Y Y, Bomgaars L. et al . Preponderance of thiopurine S-methyltransferase deficiency and heterozygosity among patients intolerant to mercaptopurine or azathioprine.  J Clin Oncol. 2001;  19 2293-2301
• 20 Fellermann K, Steffen M, Stein J. et al . Mycophenolate mofetil: lack of efficacy in chronic active inflammatory bowel disease.  Aliment Pharmacol Ther. 2000;  14 171-176
• 21 Fellermann K, Tanko Z, Herrlinger K R. et al . Response of refractory colitis to intravenous or oral tacrolimus.  Inflamm Bowel Dis. 2002;  8 317-324
• 22 Fraser A G, Orchard T R, Jewell D P. The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review.  Gut. 2002;  50 485-489
• 23 Fraser A G, Orchard T R, Robinson E M, Jewell D P. Long-term risk of malignancy after treatment of inflammatory bowel disease with azathioprine.  Aliment Pharmacol Ther. 2002;  16 1225-1232
• 24 Harms D O, Janka-Schaub G E. Co-operative study group for childhood acute lymphoblastic leukemia (COALL): long-term follow-up of trials 82, 85, 89 and 92.  Leukemia. 2000;  14 2234-2239
• 25 Herrlinger K R, Kreisel W, Schwab M. et al . 6-thioguanine - efficacy and safety in chronic active Crohn’s disease.  Aliment Pharmacol Ther. 2003;  im Druck
• 26 Hildner K, Marker-Hermann E, Schlaak J F. et al . Azathioprine, mycophenolate mofetil, and methotrexate specifically modulate cytokine production by T cells.  Ann N Y Acad Sci. 1998;  859 204-207
• 27 Kaskas B A, Louis E, Hindorf U. et al . Safe treatment of thiopurine S-methyltransferase deficient Crohn’s disease patients with azathioprine.  Gut. 2003;  52 140-142
• 28 Kroeplin T, Weyer N, Gutsche S, Iven H. Thiopurine S-methyltransferase activity in human erythrocytes: a new HPLC method using 6-thioguanine as substrate.  Eur J Clin Pharmacol. 1998;  54 265-271
• 29 Lennard L, Lilleyman J S, Van Loon J, Weinshilboum R M. Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia.  Lancet. 1990;  336 225-229
• 30 Lennard L. The clinical pharmacology of 6-mercaptopurine.  Eur J Clin Pharmacol. 1992;  43 329-339
• 31 Lennard L. Clinical implications of thiopurine methyltransferase-optimization of drug dosage and potential drug interactions.  Ther Drug Monit. 1998;  20 527-531
• 32 Lennard L. TPMT in the treatment of Crohn’s disease with azathioprine.  Gut. 2002;  51 143-146
• 33 Lewis J D, Schwartz J S, Lichtenstein G R. Azathioprine for maintenance of remission in Crohn’s disease: benefits outweigh the risk of lymphoma.  Gastroenterology. 2000;  118 1018-1024
• 34 Lewis L D, Benin A, Szumlanski C L. et al . Olsalazine and 6-mercaptopurine-related bone marrow suppression: a possible drug-drug interaction.  Clin Pharmacol Ther. 1997;  62 464-475
• 35 Lowry P W, Franklin C L, Weaver A L. et al . Leucopenia resulting from a drug interaction between azathioprine or 6-mercaptopurine and mesalamine, sulphasalazine, or balsalazide.  Gut. 2001;  49 656-664
• 36 Lowry P W, Franklin C L, Weaver A L. et al . Measurement of thiopurine methyltransferase activity and azathioprine metabolites in patients with inflammatory bowel disease.  Gut. 2001;  49 665-670
• 37 Lowry P W, Szumlanski C L, Weinshilboum R M, Sandborn W J. Balsalazide and azathiprine or 6-mercaptopurine: evidence for a potentially serious drug interaction.  Gastroenterology. 1999;  116 1505-1506
• 38 Ludwig D, Stange E F. German Imurek Study Group . Efficacy of azathioprine in the treatment of chronic active Crohn’s disease: prospective one-year follow-up study.  Z Gastroenterol. 1999;  37 1085-1091
• 39 McBride K L, Gilchrist G S, Smithson W A, Weinshilboum R M, Szumlanski C L. Severe 6-thioguanine-induced marrow aplasia in a child with acute lymphoblastic leukemia and inhibited thiopurine methyltransferase deficiency.  J Pediatr Hematol Oncol. 2000;  22 441-445
• 40 McGovern D P, Travis S P, Duley J, Shobowale-Bakre el M, Dalton H R. Azathioprine intolerance in patients with IBD may be imidazole-related and is independent of TPMT activity.  Gastroenterology. 2002;  122 838-839
• 41 McLeod H L, Siva C. The thiopurine S-methyltransferase gene locus - implications for clinical pharmacogenomics.  Pharmacogenomics. 2002;  3 89-98
• 42 Nink K, Schröder H. Ergänzende statistische Übersicht. Berlin: Springer-Verlag In: Schwabe U, Paffrath D, Hrsg. Arzneiverordnungs-Report 2001 2001: 846-930
• 43 Opelz G, Henderson R. Incidence of non-Hodgkin lymphoma in kidney and heart transplant recipients.  Lancet. 1993;  342 1514-1516
• 44 Pearson D C, May G R, Fick G H, Sutherland L R. Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis.  Ann Intern Med. 1995;  123 132-142
• 45 Persson P G, Karlen P, Bernell O. et al . Crohn’s disease and cancer: a population-based cohort study.  Gastroenterology. 1994;  107 1675-1679
• 46 Poordad F, Vasiliausless E, Abreu M. et al . Nodular regenerative hyperplasia (NRH) of the liver associated with 6-thioguanine (6-TG) therapy in inflammatory bowel disease (IBD) (abstract #680).  Hepatology. 2002;  36 333A
• 47 Present D H, Meltzer S J, Krumholz M P, Wolke A, Korelitz B I. 6-Mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity.  Ann Intern Med. 1989;  111 641-649
• 48 Russmann S, Zimmermann A, Krahenbuhl S, Kern B, Reichen J. Veno-occlusive disease, nodular regenerative hyperplasia and hepatocellular carcinoma after azathioprine treatment in a patient with ulcerative colitis.  Eur J Gastroenterol Hepatol. 2001;  13 287-290
• 49 Sandborn W J, Tremaine W J, Wolf D C. et al. North American Azathioprine Study Group . Lack of effect of intravenous administration on time to respond to azathioprine for steroid-treated Crohn’s disease.  Gastroenterology. 1999;  117 527-535
• 50 Sandborn W, Sutherland L, Pearson D, May G, Modigliani R, Prantera C. Azathioprine or 6-mercaptopurine for inducing remission of Crohn’s disease.  Cochrane Database Syst Rev. 2000;  2 CD000545
• 51 Sandborn W J. Rational dosing of azathioprine and 6-mercaptopurine.  G ut. 2001;  48 591-592
• 52 Schwab M, Klotz U. Pharmacokinetic considerations in the treatment of inflammatory bowel disease.  Clin Pharmacokinet. 2001;  40 723-751
• 53 Schwab M, Schaeffeler E, Marx C, Zanger U, Aulitzky W, Eichelbaum M. Shortcoming in the diagnosis of TPMT deficiency in a patient with Crohn’s disease using phenotyping only.  Gastroenterology. 2001;  121 498-499
• 54 Schwab M, Schaeffeler E, Marx C. et al . Azathioprine therapy and adverse drug reactions in patients with inflammatory bowel disease: impact of thiopurine S-methyltransferase polymorphism.  Pharmacogenetics. 2002;  12 429-436
• 55 Sebbag L, Boucher P, Davelu P. et al . Thiopurine S-methyltransferase gene polymorphism is predictive of azathioprine-induced myelosuppression in heart transplant recipients.  Transplantation. 2000;  69 1524-1527
• 56 Shipkova M, Armstrong V W, Wieland E, Oellerich M. Differences in Nucleotide Hydrolysis contribute to the differences between erythrocyte 6-thioguanine nucleotide concentrations determined by two widely used methods.  Clin Chem. 2003;  49 im Druck
• 57 Stange E F, Modigliani R, Pena A S, Wood A J, Feutren G, Smith P R. The European Study Group . European trial of cyclosporine in chronic active Crohn’s disease: a 12-month study.  Gastroenterology. 1995;  109 774-782
• 58 Stange E F, Riemann J, von Herbay A. et al . Diagnosis and therapy of ulcerative colitis-results of an evidence-based consensus conference of the German Society of Digestive and Metabolic Diseases.  Z Gastroenterol. 2001;  39 19-20
• 59 Stange E F, Schreiber S, Foelsch U. et al . Diagnostik und Therapie des Morbus Crohn - Ergebnisse einer evidenzbasierten Konsensuskonferenz der Deutschen Gesellschaft für Verdauungs- und Stoffwechselkrankheiten.  Z Gastroenterol. 2003;  41 19-20
• 60 Stolk L C, Broxson E H, Sather H. et al . Oral 6-thioguanine causes late-onset splenomegaly and portal hypertension in a subset of children with acute lymphoblastic leukemia (abstract T833).  Gastroenterology. 2002;  122 (Suppl)
• 61 Swann P F, Waters T R, Moulton D C. et al . Role of postreplicative DNA mismatch repair in the cytotoxic action of thioguanine.  Science. 1996;  273 1109-1111
• 62 Szumlanski C L, Weinshilboum R M. Sulphasalazine inhibition of thiopurine methyltransferase: possible mechanism for interaction with 6-mercaptopurine and azathioprine.  Br J Clin Pharmacol. 1995;  39 456-459
• 63 Tidd D M, Paterson A R. Distinction between inhibition of purine nucleotide synthesis and the delayed cytotoxic reaction of 6-mercaptopurine.  Cancer Res. 1974;  34 733-737
• 64 Tiede I, Fritz G, Wirtz S. et al . 6-Thio-GTP vermittelte funktionelle Hemmung der GTPase Rac1: Identifikation eines molekularen Wirkungsmechanismus von Azathioprin bei chronisch entzündlichen Darmerkrankungen (Abstrakt PL 6).  Z Gastroenterol. 2002;  40 603
• 65 Van Os E C, Zins B J, Sandborn W J. et al . Azathioprine pharmacokinetics after intravenous, oral, delayed release oral and rectal foam administration.  Gut. 1996;  39 63-68
• 66 Weinshilboum R M, Sladek S L. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity.  Am J Hum Genet. 1980;  32 651-662
• 67 Wood T C, Johnson K L, Naylor S, Weinshilboum R M. Cefazolin Administration and 2-Methyl-1,3,4-Thiadiazole-5-Thiol in Human Tissue: Possible Relationship to Hypoprothrombinemia.  Drug Metab Dispos. 2002;  30 1123-1128
• 68 Yates C R, Krynetski E Y, Loennechen T. et al . Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance.  Ann Intern Med. 1997;  126 608-614
• 69 Zimm S, Collins J M, O’Neill D, Chabner B A, Poplack D G. Inhibition of first-pass metabolism in cancer chemotherapy: interaction of 6-mercaptopurine and allopurinol.  Clin Pharmacol Ther. 1983;  34 810-817

1 Unterstützt durch die Robert Bosch-Stiftung, Stuttgart und das BMBF (FKZ 01 GG 9846)